Phase I study of Wilms' tumor gene WT1 peptide pulsed dendritic cell vaccination combined with docetaxel for patients with advanced or recurrent oesophageal cancer.

Trial Profile

Phase I study of Wilms' tumor gene WT1 peptide pulsed dendritic cell vaccination combined with docetaxel for patients with advanced or recurrent oesophageal cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs Tumour peptide-loaded dendritic cell vaccine Tella (Primary) ; Docetaxel
  • Indications Oesophageal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 May 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 01 Dec 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 15 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top